Saudi
Arabia’s King Abdulaziz University Hospital (KAUH) has made significant improvement in treating cancer patients with the implementation
of Elekta’s Versa HD radiotherapy system.
Versa
HD is a single treatment delivery solution with the flexibility to deliver
conventional therapies to treat a broad range of tumors throughout the body and enables the treatment of highly complex cancers that require extreme targeting
precision
“As
the cancer burden continues to grow in the kingdom of Saudi Arabia and
worldwide, we look forward to more hospitals using Elekta’s cutting-edge
technology to answer the Saudi patients’ needs in the most accurate,
comfortable, and cost-effective manner,” Elekta Middle
East Regional Sales Manager
Mouhcine Chergou
told Gulf News Journal.
As
an integrated treatment system, Versa HD offers the versatility to address growing cancer management challenges. It provides a combination of high
dose rate delivery and rapid multileaf collimator (MLC) leaf speeds along with
improved system ergonomics and clinical packages to optimize patient setup,
standardize the treatment process and enhance clinical utility.
“Elekta’s
Versa HD system is the culmination of years of research and development that
provides clinicians with an extensive range of solutions in radiotherapy – from
3-D conformal treatment to advanced and ultra-precise stereotactic
radiosurgery,”
Chergou
said. “KAUH, as a leader in cancer care in the
Gulf Cooperation Council (GCC), headed by Professor Yasir Bahadur and his team, were our perfect partner to implement this innovative
technology in record time.”
Elekta, with
the help of Faisaliah Medical Systems, its partner in Saudi Arabia, has
increased the number of its cancer treatment systems in Saudi Arabia from one to 12 in
five years, a tremendous achievement that equipped Saudi
oncologists with innovative tools in helping fight cancer in the kingdom.
Next week a panel of clinical experts from a reference university
in Germany will spend a few days with KAUH clinicians giving a symposium
on the technique and treatment of the most complex lung and brain tumors,
Chergou said.
“This
is really exciting for our Saudi partners and their patients as it expands
their horizons in cancer treatment,” Chergou said.
With
the implementation Versa HD in Saudi Arabia, Elekta, a Swedish-based human care
company with a history of many decades of providing cutting-edge solutions to
treat cancer, is trying to establish a commanding position in the fight against
cancer in the Middle East countries.
“KSA
is the first Middle East country to implement a Versa HD, with more to come
regionally,” Chergou said. “We are currently installing Versa HD
systems at the world renowned Children’s Hospital 57357 in Egypt and King Hamad (University) Hospital in Bahrain.”
“KSA, the GCC and the Middle East in general are full of clinicians that share our approach to fighting cancer and embracing
values such as innovation, dynamism, and cooperation,” Chergou said. “We look
forward to more such partnerships that will benefit the region’s clinicians as
well as the thousands of patients they treat every year.”
